Yu-Tzu Tai Selected Research

Monoclonal Gammopathy of Undetermined Significance

3/2013	MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.
10/2009	Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.
9/2009	Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yu-Tzu Tai Research Topics

Disease

128	Multiple Myeloma 06/2022 - 02/2002
68	Neoplasms (Cancer) 01/2022 - 03/2002
6	Hematologic Neoplasms (Hematological Malignancy) 12/2018 - 10/2003
5	Waldenstrom Macroglobulinemia (Macroglobulinemia) 12/2016 - 05/2006
4	Lymphoma (Lymphomas) 03/2016 - 07/2006
4	Chromosomal Instability (Chromosome Stability) 09/2015 - 07/2002
3	Bites and Stings (Sting) 12/2021 - 06/2020
3	Carcinogenesis 06/2021 - 10/2009
3	Genomic Instability 01/2021 - 03/2016
3	Monoclonal Gammopathy of Undetermined Significance 03/2013 - 09/2009
2	Paraproteinemias (Monoclonal Gammopathy) 03/2016 - 03/2013
2	Neoplasm Metastasis (Metastasis) 01/2016 - 07/2015
2	Bone Diseases (Bone Disease) 01/2016 - 07/2009
2	Bone Resorption 08/2012 - 04/2008
2	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 11/2011 - 07/2009
2	Plasmacytoma 09/2007 - 07/2007
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2021
1	Residual Neoplasm 01/2020
1	Smoldering Multiple Myeloma 01/2020

Drug/Important Bio-Agent (IBA)

21	Monoclonal AntibodiesIBA 12/2021 - 05/2003
15	Bortezomib (Velcade)FDA Link 10/2021 - 03/2003
14	Proteins (Proteins, Gene)FDA Link 10/2021 - 03/2002
13	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 12/2021 - 05/2014
11	Interleukin-6 (Interleukin 6)IBA 10/2021 - 07/2002
10	AntigensIBA 12/2021 - 05/2004
10	Proteasome InhibitorsIBA 01/2021 - 03/2003
9	Lenalidomide (CC 5013)FDA Link 01/2020 - 12/2005
9	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016 - 02/2002
8	Immunomodulating AgentsIBA 01/2021 - 12/2006
7	B-Cell Maturation AntigenIBA 12/2021 - 07/2006
7	Biological ProductsIBA 01/2020 - 08/2005
7	CytokinesIBA 10/2010 - 07/2002
6	daratumumabIBA 12/2021 - 02/2011
6	Immunoconjugates (Immunoconjugate)IBA 12/2021 - 06/2009
6	Pharmaceutical PreparationsIBA 10/2021 - 07/2005
6	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 03/2003
5	elotuzumabIBA 12/2021 - 08/2008
5	Chimeric Antigen ReceptorsIBA 12/2021 - 11/2019
5	LigandsIBA 10/2021 - 07/2006
5	Messenger RNA (mRNA)IBA 01/2021 - 08/2008
5	Histone Deacetylases (Histone Deacetylase)IBA 01/2020 - 10/2003
5	Immunoglobulin G (IgG)IBA 03/2013 - 07/2005
4	Dexamethasone (Maxidex)FDA LinkGeneric 10/2015 - 07/2005
4	MicroRNAs (MicroRNA)IBA 10/2015 - 10/2010
4	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 03/2012 - 04/2003
3	RNA (Ribonucleic Acid)IBA 01/2021 - 10/2003
3	pomalidomideIBA 01/2020 - 10/2010
3	Complement System Proteins (Complement)IBA 01/2020 - 02/2011
3	Transcription Factors (Transcription Factor)IBA 01/2019 - 09/2012
3	Histone Deacetylase InhibitorsIBA 01/2018 - 10/2003
3	Immunoglobulin M (IgM)IBA 03/2016 - 09/2007
3	EnzymesIBA 01/2014 - 10/2003
3	InterleukinsIBA 01/2009 - 05/2004
3	AntibodiesIBA 01/2008 - 03/2002
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 12/2006 - 09/2002
3	Melphalan (Alkeran)FDA LinkGeneric 12/2006 - 03/2003
3	NF-kappa B (NF-kB)IBA 07/2006 - 03/2003
3	Insulin-Like Growth Factor I (IGF-1)IBA 08/2005 - 02/2003
3	Doxorubicin (Adriamycin)FDA LinkGeneric 07/2005 - 03/2002
3	Phosphotransferases (Kinase)IBA 12/2004 - 05/2004
2	Lysine (L-Lysine)FDA Link 01/2021 - 05/2009
2	belantamab mafodotinIBA 01/2021 - 05/2014
2	Indicators and Reagents (Reagents)IBA 06/2020 - 01/2018
2	Transforming Growth Factor beta (TGF-beta)IBA 01/2020 - 07/2010
2	isatuximabIBA 01/2020 - 08/2017
2	CD40 Ligand (CD40L)IBA 01/2018 - 07/2005
2	Interleukin-10 (Interleukin 10)IBA 08/2017 - 01/2016
2	CateninsIBA 01/2017 - 03/2014
2	Nicotinamide PhosphoribosyltransferaseIBA 12/2016 - 08/2013
2	ibrutinibIBA 12/2016 - 08/2012
2	NAD (NADH)IBA 03/2016 - 10/2012
2	Tyrosine Kinase InhibitorsIBA 10/2014 - 09/2002
2	Agammaglobulinaemia Tyrosine KinaseIBA 08/2013 - 08/2012
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 10/2012 - 05/2004
2	Peptides (Polypeptides)IBA 09/2012 - 06/2012
2	Aurora Kinase AIBA 06/2010 - 09/2009
2	Immunoglobulins (Immunoglobulin)IBA 12/2009 - 03/2002
2	perifosineIBA 12/2009 - 07/2007
2	beta CateninIBA 09/2009 - 05/2007
2	Protein Kinase CIBA 02/2007 - 05/2004
2	CaspasesIBA 02/2007 - 12/2004
2	dacetuzumabIBA 12/2005 - 04/2004
2	Fibronectins (Fibronectin)IBA 07/2005 - 03/2002
2	Caveolin 1IBA 10/2004 - 02/2003
2	Tyrosine (L-Tyrosine)FDA Link 05/2004 - 05/2004
2	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2003 - 07/2002
1	nucleotidaseIBA 01/2022
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2022
1	Mitochondrial DNA (mtDNA)IBA 06/2021
1	CalreticulinIBA 01/2021
1	Positive Transcriptional Elongation Factor BIBA 01/2021
1	selinexorIBA 01/2021
1	Interferon Type IIBA 01/2021
1	histone deacetylase 3IBA 01/2020
1	Tryptophan (L-Tryptophan)FDA Link 01/2020
1	KynurenineIBA 01/2020

Therapy/Procedure

31	Therapeutics 06/2022 - 05/2003
14	Immunotherapy 01/2022 - 05/2004
3	Drug Therapy (Chemotherapy) 01/2021 - 11/2011
2	Immunomodulation 12/2021 - 01/2020